在耐火性扩散大B细胞淋巴瘤中携带CD274放大CD274的患者中,用sintilimab单独治疗的部分缓解:一个病例报告
Xian Zhang1, Liye Xu1, Evenki Pan2
1Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China.
Oncology letters
|May 13, 2024
概括
耐火性扩散性大B细胞淋巴瘤 (DLBCL) 患者可能从向治疗中受益. 下一代测序发现了CD274放大,导致用sintilimab成功治疗.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 免疫治疗是一种免疫疗法.
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种异质的血液性恶性瘤,在耐火病例中,对有效治疗的需求仍未得到满足.
- 目前的治疗方法,包括rituximab加上cyclophosphamide,doxorubicin,vincristine和prednisone (R-CHOP),在大约66%的患者中实现治愈率,突显了耐药性疾病的挑战.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
10.6K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)